NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in... Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer of the gall bladder).
- Mechanism
- Curator reviewed
Like phenoxodiol, NV-18, is able to overcome and reverse those resistance mechanisms, rendering cancer cells susceptible to standard anti-cancer drugs including those based on the taxane and platinum structures that are highly effective at killing cancer cells.
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Code names
- NV-18
Which companies are running trials of NV-18, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account